Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseaseParis, May 28, 2026. The US Food and Drug ...
People with the rare inherited metabolic disorder Gaucher disease have a deficiency in the lipid-digesting glucocerebrosidase enzyme, which causes the accumulation of harmful levels of glucolipids in ...
LONDON, May 04, 2026 (GLOBE NEWSWIRE) -- Spur Therapeutics today released new data from the GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its investigational gene therapy for Gaucher ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. Sanofi’s Cerezyme has long been used as a treatment for Gaucher disease, ...
Gregory and Deborah Macres from California lost their son, Gregory, in 1997, when he was just 4 years old. Little Gregory had a severe form of a rare genetic disorder called Gaucher disease and died ...
As gene therapies ramp up in spinal muscular atrophy and hemophilia, it may soon be the turn of Gaucher disease patients to realize the latent potential of this type of treatment. That’s according to ...
LONDON, Feb 2 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday that its experimental genetic disorder treatment showed promise in a late-stage study of patients with a type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results